Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.

Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.

Εμφάνιση άλλων εκδόσεων (1)

Many anticancer therapies, including ionizing radiation (IR), cause cytotoxicity through generation of DNA double-strand breaks (DSB). Delivery of therapeutic radionuclides to DNA DSB sites can amplify this DNA damage, for additional therapeutic gain. Herein, we report on two radiopharmaceuticals, r...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Cornelissen, B, Waller, A, Able, S, Vallis, K
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	American Association for Cancer Research 2013

Παρόμοια τεκμήρια

Molecular radiotherapy using cleavable radioimmunoconjugates that target eGFR and γH2AX
ανά: Cornelissen, B, κ.ά.
Έκδοση: (2013)

Can γH2AX be used to personalise cancer treatment?
ανά: Shah, K, κ.ά.
Έκδοση: (2013)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical
ανά: Cornelissen, B, κ.ά.
Έκδοση: (2012)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
ανά: Cornelissen, B, κ.ά.
Έκδοση: (2012)

γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies
ανά: Shah, K, κ.ά.
Έκδοση: (2015)

Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.
ανά: Cornelissen, B, κ.ά.
Έκδοση: (2011)

Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR
ανά: Luke Yongkyu Kwon, κ.ά.
Έκδοση: (2024-05-01)

New radioimmunoconjugate -dota-h-r3. synthesis and radiolabeling
ανά: Denis R. Beckford Vera, κ.ά.
Έκδοση: (2007-01-01)

EP-2324: Non-invasive PET imaging of radiosensitive tumour regions using γH2AX-targeted immunoconjugate
ανά: Yaromina, A, κ.ά.
Έκδοση: (2018)

The Phosphorylated Form of the Histone H2AX (γH2AX) in the Brain from Embryonic Life to Old Age
ανά: Adalberto Merighi, κ.ά.
Έκδοση: (2021-11-01)

The kinetics of γ-H2AX during radiotherapy of head and neck cancer potentially allow for prediction of severe mucositis
ανά: Kazmierska Joanna, κ.ά.
Έκδοση: (2020-02-01)

Intracellular delivery of radioimmunoconjugates that target the cancer testis antigen, NY-ESO-1
ανά: Chu, H
Έκδοση: (2013)

Generation of an alpaca‐derived nanobody recognizing γ‐H2AX
ανά: Malini Rajan, κ.ά.
Έκδοση: (2015-01-01)

Predictive effect of γH2AX expression on the radiosensitivity of glioma
ανά: Jun-wei WANG, κ.ά.
Έκδοση: (2014-03-01)

In vivo Analysis of H2AX Phosphorylation Induced by γ-Radiation
ανά: Seyed Mostafa Mir, κ.ά.
Έκδοση: (2017-03-01)

PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.
ανά: Knight, J, κ.ά.
Έκδοση: (2015)

On cleavability
ανά: Levine, S
Έκδοση: (2012)

Accumulation of 111In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Co-administration of Targeting Ligand
ανά: Song, L, κ.ά.
Έκδοση: (2017)

PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates
ανά: Knight, J, κ.ά.
Έκδοση: (2015)

Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
ανά: Lourenço, J
Έκδοση: (2024)

89Zr-anti-γH2AX-TAT allows early monitoring of response to gemcitabine and capecitabine therapy in pancreatic ductal adenocarcinoma
ανά: Knight, J, κ.ά.
Έκδοση: (2016)

Residual γH2AX foci as an indication of lethal DNA lesions
ανά: Banuelos C Adriana, κ.ά.
Έκδοση: (2010-01-01)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
ανά: Cornelissen, B, κ.ά.
Έκδοση: (2008)

Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
ανά: Glatting, G, κ.ά.
Έκδοση: (2006)

Increased γ-H2A.X intensity in response to chronic medium-dose-rate γ-ray irradiation.
ανά: Takashi Sugihara, κ.ά.
Έκδοση: (2012-01-01)

Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery
ανά: Guanren Zhao, κ.ά.
Έκδοση: (2017-06-01)

DNA Damage Sensor γ-H2AX Is Increased in Preneoplastic Lesions of Hepatocellular Carcinoma
ανά: Yasunobu Matsuda, κ.ά.
Έκδοση: (2013-01-01)

A portable microfluidic fluorescence spectrometer device for γ-H2AX-based biological dosimetry
ανά: Pope, I, κ.ά.
Έκδοση: (2011)

Developable spaces and cleavability
ανά: F. CAMMAROTO, κ.ά.
Έκδοση: (1994-09-01)

EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
ανά: Song, L, κ.ά.
Έκδοση: (2016)

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma
ανά: Ashleigh Hull, κ.ά.
Έκδοση: (2022-09-01)

Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma
ανά: Raquel Benedetto, κ.ά.
Έκδοση: (2018-04-01)

ATM and SIRT6/SNF2H Mediate Transient H2AX Stabilization When DSBs Form by Blocking HUWE1 to Allow Efficient γH2AX Foci Formation
ανά: Yuko Atsumi, κ.ά.
Έκδοση: (2015-12-01)

Imaging DNA damage response (DDR) during oncogenesis
ανά: Cornelissen, B, κ.ά.
Έκδοση: (2013)

Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy
ανά: Kersemans, V, κ.ά.
Έκδοση: (2010)

Radiation exposure lymphocyte damage assessed by γ-H2AX level using flow cytometry
ανά: Zhuoqing Chen, κ.ά.
Έκδοση: (2024-02-01)

PARP1 exhibits enhanced association and catalytic efficiency with γH2A.X-nucleosome
ανά: Deepti Sharma, κ.ά.
Έκδοση: (2019-12-01)

Development of a high-throughput γ-H2AX assay based on imaging flow cytometry
ανά: Younghyun Lee, κ.ά.
Έκδοση: (2019-08-01)

Positioning of nucleosomes containing γ-H2AX precedes active DNA demethylation and transcription initiation
ανά: Stephanie Dobersch, κ.ά.
Έκδοση: (2021-02-01)

Cohesin protects genes against γH2AX Induced by DNA double-strand breaks.
ανά: Pierre Caron, κ.ά.
Έκδοση: (2012-01-01)